Providers

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial treatment, as well as the changing landscape of multiple myeloma treatment.

A significant number of patients taking Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL) develop atrial fibrillation (AF).

Two studies explored the quality-of-life impacts of lebrikizumab for atopic dermatitis, finding its benefits extend beyond physical symptom improvements.

Despite holding promise in a range of disease states, a variety of challenges prevent cell and gene therapies (CGTs) from more widespread use, according to a new report from Cardinal Health.

The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.

Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial participation among patients with the 2 autoimmune diseases.

Multidisciplinary efforts help promote the success of clinical trials and innovation for patients with various forms of lymphoma, explained Andrew Evens, DO.

Stephen Speicher, MD, and Kate Estep, from Flatiron Health, discuss the future of oncology care with artificial intelligence (AI).

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis (MASH) and severe fibrosis.

Individuals with rheumatoid arthritis face a higher risk of hospitalization for heart failure and pulmonary edema, a new report found.

Primary care nurse practitioners were found to use low-value care at lower or relatively similar rates compared with the general clinician population.

A study reveals higher health care costs and resource use for uncomplicated urinary tract infections (uUTIs), emphasizing the need for improved patient management strategies.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

Patients with a high tumor burden score had poorer outcomes following microwave ablation, the investigators found.

The impact of psoriasis on quality of life goes beyond clinical measures, such as psoriasis area severity index (PASI) and body surface area (BSA), a study finds.

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase patient access, but also improve the overall wellbeing, experience, and outcomes for this population.

Antoine Keller, MD, discussed the future impact of technological advances for cardiovascular (CV) care and what other elements contribute to quality, accessible health care.

A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year.

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated with a daratumumab quadruplet regimen.

K. "Vish" Viswanath, PhD, discusses the impact of misinformation on trust in health care, emphasizing the importance of reliable sources and patient-physician communication.

To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.